Pyrogen Test Expectations for Pharmaceutical Manufacturing

Pyrogen control is a critical element of pharmaceutical quality assurance for parenteral products and selected medical devices. Bacterial endotoxins derived from Gram negative bacteria present the predominant pyrogenic risk due to their high potency, resistance to standard sterilization processes, and widespread occurrence in manufacturing environments. Historically, pyrogen testing has relied on in vivo and in vitro methods such as the Rabbit Pyrogen Test (RPT), Bacterial Endotoxins Test (BET), and Monocyte Activation Test (MAT). The introduction of European Pharmacopoeia chapter 5.1.13 in January 2025 formalized a risk based approach for selecting appropriate pyrogen detection methods. Manufacturers are now expected to perform and document a product and process specific pyrogen risk assessment when justifying exclusive reliance on endotoxin specific testing. This article reviews the principal classes of pyrogens relevant to pharmaceutical manufacturing, evaluates their potency, stability, and likelihood of occurrence, and discusses critical control points and mitigation strategies in sterile injectable processes. A pragmatic framework for implementing pyrogen risk assessment in accordance with Ph. Eur. 5.1.13 is proposed to support robust pyrogen control and patient safety.